Browsing Tag
Molecular residual disease
2 posts
Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition
Exact Sciences delivered record 2025 results ahead of its Abbott acquisition. Find out why cash flow, screening scale, and timing matter now.
Natera boosts ctDNA and lymphoma detection capabilities through Foresight Diagnostics acquisition
Find out how Natera’s acquisition of Foresight Diagnostics could redefine ultra-sensitive cancer detection and reshape the future of MRD testing.